Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Addex Therapeutics Ltd
  6. Financials
    ADXN   CH0029850754

ADDEX THERAPEUTICS LTD

(ADXN)
  Report
Delayed Swiss Exchange  -  11:30 2022-12-02 am EST
0.1362 CHF   +4.77%
11/14Addex Therapeutics : INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K
PU
11/11Transcript : Addex Therapeutics Ltd, Q3 2022 Earnings Call, Nov 11, 2022
CI
11/11Addex Therapeutics Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 43,453,239,414,1--
Enterprise Value (EV)1 12,134,519,49,438,0515,4
P/E ratio -2,93x-4,15x-2,31x-0,33x-0,79x-0,68x
Yield ------
Capitalization / Revenue 15,7x13,7x12,5x14,8x26,0x-
EV / Revenue 4,37x8,89x6,15x9,90x14,9x-
EV / EBITDA -0,85x-2,91x-1,28x-0,71x-1,20x-2,30x
Price to Book 1,71x3,69x2,33x2,72x2,21x-1,87x
Nbr of stocks (in thousands) 26 48526 75437 903103 234--
Reference price (CHF) 1,641,991,040,140,140,14
Announcement Date 04/08/202003/11/202103/10/2022---
1 CHF in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 2,763,883,150,950,54-
EBITDA1 -14,3-11,9-15,2-13,3-6,70-6,70
Operating profit (EBIT)1 -14,6-12,2-15,5-17,9-10,0-8,05
Operating Margin -529%-316%-492%-1 877%-1 856%-
Pre-Tax Profit (EBT)1 -14,8-12,9-15,4-17,5-9,60-7,10
Net income1 -14,8-12,9-15,4-17,5-9,60-7,10
Net margin -535%-332%-487%-1 833%-1 778%-
EPS2 -0,56-0,48-0,45-0,41-0,17-0,20
Dividend per Share2 ------
Announcement Date 04/08/202003/11/202103/10/2022---
1 CHF in Million
2 CHF
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales1 0,240,190,420,250,300,30
EBITDA ------
Operating profit (EBIT)1 -5,76-7,09-4,17-3,15--
Operating Margin -2 362%-3 813%-1 002%-1 260%--
Pre-Tax Profit (EBT)1 -5,82-7,22-4,11-3,20--
Net income1 -5,82-7,22-4,11-3,20--
Net margin -2 387%-3 882%-988%-1 280%--
EPS2 -0,15-0,19-0,09-0,05-0,05-0,04
Dividend per Share ------
Announcement Date 05/05/202207/30/202211/11/2022---
1 CHF in Million
2 CHF
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 -----1,35
Net Cash position1 31,418,820,04,636,01-
Leverage (Debt / EBITDA) 2,20x1,58x1,32x0,35x0,90x-0,20x
Free Cash Flow -9,51-12,2-14,7---
ROE (Net Profit / Equities) ------
Shareholders' equity1 ------
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share2 0,960,540,450,050,06-0,07
Cash Flow per Share -0,36-0,46-0,43---
Capex1 -0,060,030,300,300,30
Capex / Sales -1,53%1,00%31,5%55,6%-
Announcement Date 04/08/202003/11/202103/10/2022---
1 CHF in Million
2 CHF
Previous periodNext period
Estimates
Key data
Capitalization (CHF) 14 060 430
Capitalization (USD) 14 966 821
Net sales (CHF) 3 153 000
Net sales (USD) 3 356 255
Number of employees 26
Sales / Employee (CHF) 121 269
Sales / Employee (USD) 129 087
Free-Float 71,0%
Free-Float capitalization (CHF) 9 985 812
Free-Float capitalization (USD) 10 629 536
Avg. Exchange 20 sessions (CHF) 9 689
Avg. Exchange 20 sessions (USD) 10 313
Average Daily Capital Traded 0,07%
EPS & Dividend